Literature DB >> 25650174

DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers.

Aaron S Mansfield1, Liang Wang2, Julie M Cunningham3, Jin Jen4, Christopher P Kolbert5, Zhifu Sun6, Ping Yang7.   

Abstract

Lung cancer occurs in never-smokers. Epigenetic changes in lung cancer potentially represent important diagnostic, prognostic, and therapeutic targets. We compared DNA methylation profiles of 28 adenocarcinomas of the lungs of never-smokers with paired adjacent nonmalignant lung tissue. We correlated differential methylation changes with gene expression changes from the same 28 sample pairs. Using principal component analysis, we observed a distinct separation in methylation profiles between tumor and adjacent nonmalignant lung tissue. Tumors were generally hypomethylated compared with adjacent nonmalignant tissue. Of 1,906 CpG sites differentially methylated between tumor and nonmalignant tissue, 1,198 were within classically defined CpG islands where tumors were hypermethylated compared with nonmalignant tissue. A total of 708 sites were outside CpG islands where tumors were hypomethylated compared with nonmalignant tissue. There were significant differences in expression of 351 genes (23%) of the 1,522 genes matched to the differentially methylated CpG sites. Genes that were not significantly differentially expressed and were hypermethylated within CpG sites were enriched for homeobox genes. These results suggest that the methylation profiles of lung adenocarcinomas of never-smokers and adjacent nonmalignant lung tissue are significantly different. Despite the differential methylation of homeobox genes, no significant changes in expression of these genes were detected.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle; DNA methylation; epigenetics; gene expression; homeobox; lung adenocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 25650174      PMCID: PMC4465988          DOI: 10.1016/j.cancergen.2014.12.002

Source DB:  PubMed          Journal:  Cancer Genet


  33 in total

Review 1.  The Cdx-1 and Cdx-2 homeobox genes in the intestine.

Authors:  J N Freund; C Domon-Dell; M Kedinger; I Duluc
Journal:  Biochem Cell Biol       Date:  1998       Impact factor: 3.626

2.  Faster cyclic loess: normalizing RNA arrays via linear models.

Authors:  Karla V Ballman; Diane E Grill; Ann L Oberg; Terry M Therneau
Journal:  Bioinformatics       Date:  2004-05-27       Impact factor: 6.937

Review 3.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

4.  CpG islands in vertebrate genomes.

Authors:  M Gardiner-Garden; M Frommer
Journal:  J Mol Biol       Date:  1987-07-20       Impact factor: 5.469

5.  Alpha1-antitrypsin deficiency allele carriers among lung cancer patients.

Authors:  P Yang; K A Wentzlaff; J A Katzmann; R S Marks; M S Allen; T G Lesnick; N M Lindor; J L Myers; E Wiegert; D E Midthun; S N Thibodeau; M J Krowka
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-05       Impact factor: 4.254

6.  Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.

Authors:  Mathewos Tessema; Christin M Yingling; Yushi Liu; Carmen S Tellez; Leander Van Neste; Stephen S Baylin; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2014-01-07       Impact factor: 4.944

7.  Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation.

Authors:  David Waltregny; Younes Alami; Nathalie Clausse; Jean de Leval; Vincent Castronovo
Journal:  Prostate       Date:  2002-02-15       Impact factor: 4.104

8.  Altered expressions of HOX genes in human cutaneous malignant melanoma.

Authors:  Kazuhiko Maeda; Jun-Ichi Hamada; Yoko Takahashi; Mitsuhiro Tada; Yuhei Yamamoto; Tsuneki Sugihara; Tetsuya Moriuchi
Journal:  Int J Cancer       Date:  2005-04-10       Impact factor: 7.396

Review 9.  Epigenetics in human disease and prospects for epigenetic therapy.

Authors:  Gerda Egger; Gangning Liang; Ana Aparicio; Peter A Jones
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

View more
  6 in total

1.  Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation.

Authors:  Fuhua Yang; Qiang Gong; Wentao Shi; Yunding Zou; Jingmin Shi; Fengjiang Wei; Qingrong Li; Jieping Chen; Wei-Dong Li
Journal:  Tumour Biol       Date:  2016-07-12

2.  Evaluation of the Methylation and Acetylation Profiles of Dinitroaniline Herbicides and Resveratrol on the V79 Cell Line.

Authors:  Zehra Sarıgöl Kılıç; Tuğbagül Çal; Ülkü Ündeğer Bucurgat
Journal:  Turk J Pharm Sci       Date:  2020-12-23

3.  Identification of Methylation-Driven, Differentially Expressed STXBP6 as a Novel Biomarker in Lung Adenocarcinoma.

Authors:  Govinda Lenka; Mong-Hsun Tsai; Hsin-Chieh Lin; Jen-Hao Hsiao; Yi-Ching Lee; Tzu-Pin Lu; Jang-Ming Lee; Chung-Ping Hsu; Liang-Chuan Lai; Eric Y Chuang
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

4.  A novel CpG island methylation panel predicts survival in lung adenocarcinomas.

Authors:  Pingzhao Yan; Xiaohua Yang; Jianhua Wang; Shichang Wang; Hong Ren
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

5.  CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma.

Authors:  Haiwei Wang; Xinrui Wang; Liangpu Xu; Yingying Lin; Ji Zhang
Journal:  Dis Markers       Date:  2022-07-28       Impact factor: 3.464

6.  Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

Authors:  Maria Moksnes Bjaanæs; Thomas Fleischer; Ann Rita Halvorsen; Antoine Daunay; Florence Busato; Steinar Solberg; Lars Jørgensen; Elin Kure; Hege Edvardsen; Anne-Lise Børresen-Dale; Odd Terje Brustugun; Jörg Tost; Vessela Kristensen; Åslaug Helland
Journal:  Mol Oncol       Date:  2015-11-06       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.